{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+40+mg%3A&page=6", "query": { "intervention": "Drug 40 mg:", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1060, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+40+mg%3A&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+40+mg%3A&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T20:15:51.591Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01101035", "title": "Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Febuxostat", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 6198, "start_date": "2010-04-23", "completion_date": "2017-07-18", "has_results": true, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 202, "location_summary": "Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Dunwoody", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Norcross", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101035" }, { "nct_id": "NCT07354074", "title": "Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia", "Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Asciminib single agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 50, "start_date": "2026-04-28", "completion_date": "2033-02-23", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • New York, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07354074" }, { "nct_id": "NCT01393990", "title": "A Study of LY2228820 in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "LY2228820", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2008-09-04", "completion_date": "2013-12-14", "has_results": true, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 2, "location_summary": "Rochester, Minnesota • San Antonio, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393990" }, { "nct_id": "NCT01504659", "title": "Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Ketamine hydrochloride injection", "type": "DRUG" }, { "name": "Flat tonic water (e.g., Canada Dry Tonic Water)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juvenile Bipolar Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 5, "start_date": "2012-07", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2017-03-16", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 4, "location_summary": "Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more", "locations": [ { "city": "Not Predetermined", "state": "Connecticut" }, { "city": "Maplewood", "state": "New Jersey" }, { "city": "Not Predetermined", "state": "New Jersey" }, { "city": "Not Predetermined", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01504659" }, { "nct_id": "NCT04963283", "title": "Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Colon Cancer", "Colon Adenocarcinoma", "Rectum Cancer", "Rectal Cancer", "Rectal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-06-23", "completion_date": "2027-02-09", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 5, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Loveland", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963283" }, { "nct_id": "NCT00309842", "title": "Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelofibrosis", "MDS", "Refractory Anemia", "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Non-Hodgkin's Lymphoma", "Leukemia", "Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 213, "start_date": "2005-07-28", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2020-09-10", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Seattle, Washington", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309842" }, { "nct_id": "NCT04711005", "title": "Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "(2R,6R)-Hydroxynorketamine hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2021-01-11", "completion_date": "2023-05-31", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711005" }, { "nct_id": "NCT05686239", "title": "A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairment Associated With Schizophrenia (CIAS)", "Cognitive Impairment", "Schizophrenia" ], "interventions": [ { "name": "RL-007 (Inidascamine)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Recognify Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 242, "start_date": "2022-12-08", "completion_date": "2025-04-09", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 20, "location_summary": "Culver City, California • Garden Grove, California • Lafayette, California + 17 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lafayette", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686239" }, { "nct_id": "NCT03578367", "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CML", "Chronic Myelogenous Leukemia", "Leukemia, Myeloid Chronic", "Hematologic Diseases" ], "interventions": [ { "name": "Asciminib add-on", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Asciminib 80mg QD (asciminib single agent (ASAC))", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 104, "start_date": "2018-11-22", "completion_date": "2025-02-26", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 2, "location_summary": "Augusta, Georgia • Baltimore, Maryland", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578367" }, { "nct_id": "NCT03719586", "title": "Investigational Therapeutics for the Treatment of People With Ebola Virus Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ebola Virus" ], "interventions": [ { "name": "ZMapp", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "MAb114", "type": "DRUG" }, { "name": "REGN-EB3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "99 Years", "sex": "ALL", "summary": "Up to 99 Years" }, "enrollment_count": 681, "start_date": "2018-11-21", "completion_date": "2020-08-18", "has_results": true, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-10-12T20:15:51.591Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719586" } ] }